The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...

Boston Scientific ( (BSX) ) just unveiled an announcement. Boston Scientific Corporation has announced the resumption of its AVANT GUARD ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...